Page 2116 - Williams Hematology ( PDFDrive )

2090 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2091

268. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 bleeding complications in essential thrombocythaemia and polycythaemia vera. Plate-
in human myeloproliferative disorders. Lancet 365(9464):1054–1061, 2005. lets 15(2):67–84, 2004.
269. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 299. Rinder HM, Schuster JE, Rinder CS, et al: Correlation of thrombosis with increased
in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelo- platelet turnover in thrombocytosis. Blood 91(4):1288–1294, 1998.
fibrosis. Cancer Cell 7(4):387–397, 2005. 300. Besses C, Cervantes F, Pereira A, et al: Major vascular complications in essential throm-
270. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to consti- bocythemia: A study of the predictive factors in a series of 148 patients. Leukemia
tutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148, 2005. 13(2):150–154, 1999.
271. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in 301. Barbui T, Barosi G, Grossi A, et al: Practice guidelines for the therapy of essential
myeloproliferative disorders. N Engl J Med 352(17):1779–1790, 2005. thrombocythemia. A statement from the Italian Society of Hematology, the Italian
272. Scott LM, Tong W, Levine RL, et al: JAK2 exon 12 mutations in polycythemia vera and Society of Experimental Hematology and the Italian Group for Bone Marrow Trans-
idiopathic erythrocytosis. N Engl J Med 356(5):459–468, 2007. plantation. Haematologica 89(2):215–232, 2004.
273. Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myeloproliferative and 302. De Stefano V, Za T, Rossi E, et al: Recurrent thrombosis in patients with polycythemia
other myeloid disorders: A study of 1182 patients. Blood 108(10):3472–3476, 2006. vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments.
274. Schnittger S, Bacher U, Haferlach C, et al: Characterization of 35 new cases with four Haematologica 93(3):372–380, 2008.
different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. 303. Finazzi G, Carobbio A, Thiele J, et al: Incidence and risk factors for bleeding in 1104
Haematologica 94(1):141–144, 2009. patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed
275. Nangalia J, Massie CE, Baxter EJ, et al: Somatic CALR mutations in myeloproliferative according to the 2008 WHO criteria. Leukemia 26(4):716–719, 2012.
neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405, 2013. 304. Schafer AI: Molecular basis of the diagnosis and treatment of polycythemia vera and
276. Klampfl T, Gisslinger H, Harutyunyan AS, et al: Somatic mutations of calreticulin in essential thrombocythemia. Blood 107(11):4214–4222, 2006.
myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390, 2013. 305. Beer PA, Erber WN, Campbell PJ, Green AR: How I treat essential thrombocythemia.
277. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al: Increased platelet and leuko- Blood 117(5):1472–1482, 2011.
cyte activation as contributing mechanisms for thrombosis in essential thrombocythe- 306. Vannucchi AM: How I treat polycythemia vera. Blood 124(22):3212–3220, 2014.
mia and correlation with the JAK2 mutational status. Haematologica 91(2):169–175, 307. Spivak J: Daily aspirin—Only half the answer. N Engl J Med 350(2):99–101, 2004.
2006. 308. Marchioli R, Finazzi G, Specchia G, et al; CYTO-PV Collaborative Group: Cardiovas-
278. Falanga A, Marchetti M, Vignoli A, et al: V617F JAK-2 mutation in patients with essen- cular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–
tial thrombocythemia: Relation to platelet, granulocyte, and plasma hemostatic and 33, 2013.
inflammatory molecules. Exp Hematol 35(5):702–711, 2007. 309. Kaplan ME, Mack K, Goldberg JD, et al: Long-term management of polycythemia vera
279. Robertson B, Urquhart C, Ford I, et al: Platelet and coagulation activation markers in with hydroxyurea: A progress report. Semin Hematol 23(3):167–171, 1986.
myeloproliferative diseases: Relationships with JAK2 V6I7 F status, clonality, and anti- 310. Gilbert HS: Modern treatment strategies in polycythemia vera. Semin Hematol 40(1
phospholipid antibodies. J Thromb Haemost 5(8):1679–1685, 2007. Suppl 1):26–29, 2003.
280. Coucelo M, Caetano G, Sevivas T, et al: JAK2V617F allele burden is associated with 311. Barbui T, Finazzi G: Treatment indications and choice of a platelet-lowering agent in
thrombotic mechanisms activation in polycythemia vera and essential thrombocythe- essential thrombocythemia. Curr Hematol Rep 2(3):248–256, 2003.
mia patients. Int J Hematol 99(1):32–40, 2014. 312. Cortelazzo S, Finazzi G, Ruggeri M, et al: Hydroxyurea for patients with essential
281. Pemmaraju N, Moliterno AR, Williams DM, et al: The quantitative JAK2 V617F neu- thrombocythemia and a high risk of thrombosis. N Engl J Med 332(17):1132–1136,
trophil allele burden does not correlate with thrombotic risk in essential thrombocyto- 1995.
sis. Leukemia 21(10):2210–2212, 2007. 313. Pescatore SL, Lindley C: Anagrelide: A novel agent for the treatment of myeloprolifera-
282. Rumi E, Harutyunyan AS, Pietra D, et al; Associazione Italiana per la Ricerca sul tive disorders. Expert Opin Pharmacother 1(3):537–546, 2000.
Cancro Gruppo Italiano Malattie Mieloproliferative I. CALR exon 9 mutations are 314. Emadi A, Spivak JL: Anagrelide: 20 years later. Expert Rev Anticancer Ther 9(1):37–50,
somatically acquired events in familial cases of essential thrombocythemia or primary 2009.
myelofibrosis. Blood 123(15):2416–2419, 2014. 315. Solberg LA Jr, Tefferi A, Oles KJ, et al: The effects of anagrelide on human megakaryo-
283. Andrikovics H, Krahling T, Balassa K, et al: Distinct clinical characteristics of myelopro- cytopoiesis. Br J Haematol 99(1):174–180, 1997.
liferative neoplasms with calreticulin mutations. Haematologica 99(7):1184–1190, 2014. 316. Fruchtman SM, Petitt RM, Gilbert HS, et al: Anagrelide: Analysis of long-term efficacy,
284. Tefferi A, Wassie EA, Guglielmelli P, et al: Type 1 versus Type 2 calreticulin mutations safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 29(5):481–
in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol 491, 2005.
89(8):E121–E124, 2014. 317. Wagstaff AJ, Keating GM: Anagrelide: A review of its use in the management of essen-
285. Rotunno G, Mannarelli C, Guglielmelli P et al; Associazione Italiana per la Ricerca sul tial thrombocythaemia. Drugs 66(1):111–131, 2006.
Cancro Gruppo Italiano Malattie Mieloproliferative I. Impact of calreticulin mutations 318. Campbell PJ, Scott LM, Buck G, et al: Definition of subtypes of essential thrombocy-
on clinical and hematological phenotype and outcome in essential thrombocythemia. thaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A
Blood 123(10):1552–1555, 2014. prospective study. Lancet 366(9501):1945–1953, 2005.
286. Mitchell MC, Boitnott JK, Kaufman S, et al: Budd-Chiari syndrome: Etiology, diagnosis 319. Hultdin M, Sundstrom G, Wahlin A, et al: Progression of bone marrow fibrosis in
and management. Medicine (Baltimore) 61(4):199–218, 1982. patients with essential thrombocythemia and polycythemia vera during anagrelide
287. Murphy S: Thrombocytosis and thrombocythaemia. Clin Haematol 12(1):89–106, treatment. Med Oncol 24(1):63–70, 2007.
1983. 320. Gisslinger H, Gotic M, Holowiecki J, et al; ANAHYDRET Study Group: Anagrelide
288. Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood compared with hydroxyurea in WHO-classified essential thrombocythemia: The
64(1):1–12, 1984. ANAHYDRET Study, a randomized controlled trial. Blood 121(10):1720–1728, 2013.
289. Gangat N, Wolanskyj AP, Tefferi A: Abdominal vein thrombosis in essential thrombo- 321. Mohri H, Noguchi T, Kodama F, et al: Acquired von Willebrand disease due to inhib-
cythemia: Prevalence, clinical correlates, and prognostic implications. Eur J Haematol itor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol
77(4):327–333, 2006. 87(5):663–668, 1987.
290. Yonal I, Pinarbasi B, Hindilerden F, et al: The clinical significance of JAK2V617F muta- 322. Michiels JJ, Abels J, Steketee J, et al: Erythromelalgia caused by platelet-mediated arte-
tion for Philadelphia-negative chronic myeloproliferative neoplasms in patients with riolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102(4):466–
splanchnic vein thrombosis. J Thromb Thrombolysis 34(3):388–396, 2012. 471, 1985.
291. Smalberg JH, Arends LR, Valla DC, et al: Myeloproliferative neoplasms in Budd- 323. van Genderen PJ, Prins FJ, Lucas IS, et al: Decreased half-life time of plasma von Wille-
Chiari syndrome and portal vein thrombosis: A meta-analysis. Blood 120(25): brand factor collagen binding activity in essential thrombocythaemia: Normalization
4921–4928, 2012. after cytoreduction of the increased platelet count. Br J Haematol 99(4):832–836, 1997.
292. Valla D, Casadevall N, Huisse MG, et al: Etiology of portal vein thrombosis in adults. 324. Pascale S, Petrucci G, Dragani A, et al: Aspirin-insensitive thromboxane biosynthesis in
A prospective evaluation of primary myeloproliferative disorders. Gastroenterology essential thrombocythemia is explained by accelerated renewal of the drug target. Blood
94(4):1063–1069, 1988. 119(15):3595–3603, 2012.
293. Hoekstra J, Janssen HL: Vascular liver disorders (II): Portal vein thrombosis. Neth J Med 325. Cavalca V, Rocca B, Squellerio I, et al: In vivo prostacyclin biosynthesis and effects of
67(2):46–53, 2009. different aspirin regimens in patients with essential thrombocythaemia. Thromb Hae-
294. Hoekstra J, Janssen HL: Vascular liver disorders (I): Diagnosis, treatment and prognosis most 112(1):118–127, 2014.
of Budd-Chiari syndrome. Neth J Med 66(8):334–339, 2008. 326. Landolfi R, Marchioli R, Kutti J, et al: Efficacy and safety of low-dose aspirin in poly-
295. Frewin R, Dowson A: Headache in essential thrombocythaemia. Int J Clin Pract cythemia vera. N Engl J Med 350(2):114–124, 2004.
66(10):976–983, 2012. 327. Gangat N, Wolanskyj AP, Schwager S, Tefferi A: Predictors of pregnancy outcome in
296. Singh AK, Wetherley-Mein G: Microvascular occlusive lesions in primary thrombocy- essential thrombocythemia: A single institution study of 63 pregnancies. Eur J Haema-
thaemia. Br J Haematol 36(4):553–564, 1977. tol 82(5):350–353, 2009.
297. van Genderen PJ, Terpstra W, Michiels JJ, et al: High-dose intravenous immunoglob- 328. Passamonti F, Randi ML, Rumi E, et al: Increased risk of pregnancy complications in
ulin delays clearance of von Willebrand factor in acquired von Willebrand disease. patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood
Thromb Haemost 73(5):891–892, 1995. 110(2):485–489, 2007.
298. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH: Pathophysiology and treat- 329. Barbui T, Finazzi G: Myeloproliferative disease in pregnancy and other management
ment of platelet-mediated microvascular disturbances, major thrombosis and issues. Hematology Am Soc Hematol Educ Program 246–252, 2006.

Kaushansky_chapter 121_p2073-2096.indd 2091 9/18/15 10:28 AM